Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Capsules
Reexamination Certificate
2011-04-12
2011-04-12
Azpuru, Carlos A (Department: 1617)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Capsules
C424S464000
Reexamination Certificate
active
07923025
ABSTRACT:
The present invention relates to an agent for inhibiting decomposition of a biologically active peptide by a digestive enzyme, which is aminoalkyl methacrylate copolymer E as an effective ingredient, and an agent for reducing viscosity of the gastrointestinal mucosa and mucous layers distributed over this mucosa. The present invention relates to a method for inhibiting decomposition of a biologically active peptide by a digestive enzyme, or a method for reducing viscosity of the gastrointestinal mucosa and/or mucous layers distributed over the mucosa, by administration of aminoalkyl methacrylate copolymer E. Furthermore, the present invention relates to a pharmaceutical composition for oral use with improved absorption, which comprises a biologically active peptide and aminoalkyl methacrylate copolymer E. Excellent oral absorption of a biologically active peptide that were considered difficult to absorb by oral administration in the past, can be realized based on the ability to inhibit decomposition of a biologically active peptide, the ability to reduce viscosity of the gastrointestinal mucosa and/or mucous layers distributed over this mucosa, and the ability to improve permeability of a biologically active peptide in the gastrointestinal mucosa and/or mucous layers of the pharmaceutical composition of the present invention.
REFERENCES:
patent: 4537772 (1985-08-01), Alexander et al.
patent: 5350741 (1994-09-01), Takada
patent: 5445830 (1995-08-01), Ishizue et al.
patent: 5726154 (1998-03-01), Baudys et al.
patent: 5766620 (1998-06-01), Heiber et al.
patent: 5849322 (1998-12-01), Ebert et al.
patent: 6004575 (1999-12-01), Luessen et al.
patent: 6368635 (2002-04-01), Akiyama et al.
patent: 6458383 (2002-10-01), Chen et al.
patent: 7008640 (2006-03-01), Watanabe et al.
patent: 2002/0150624 (2002-10-01), Watanabe et al.
patent: 2005/0112206 (2005-05-01), Watanabe et al.
patent: 0759303 (1997-02-01), None
patent: 1093818 (1999-01-01), None
patent: 1 093 818 (2001-04-01), None
patent: 1093818 (2001-04-01), None
patent: 1273306 (2003-01-01), None
patent: 7138182 (1995-05-01), None
patent: 9278670 (1997-10-01), None
patent: WO 90/01329 (1990-02-01), None
patent: WO 96/06635 (1996-03-01), None
patent: WO 00/02574 (2000-01-01), None
patent: WO 00/43041 (2000-07-01), None
patent: WO 02/05786 (2002-01-01), None
Asada et al., “Absorption Characteristics of Chemically Modified-Insulin Derivatives with Various Fatty Acids in the Small and Large Intestine,”Journal of Pharmaceutical Sciences, Jun. 1995, pp. 682-687, vol. 84, No. 6.
Hochman et al., “Mechanisms of Absorption Enhancement and Tight Junction Regulation,”Journal of Controlled Release, 1994, pp. 253-267, vol. 29.
Kotzé et al., “Chitosans for Enhanced Delivery of Therapeutic Peptides Across Intestinal Epithelia: In Vitro Evaluation in Caco-2 Cell Monolayers,”International Journal of Pharmaceutics, 1997, pp. 243-253, vol. 159.
Luessen et al., “Mucoadhesive Polymers in Peroral Peptide Drug Delivery. V. Effect of Poly(acrylates) on the Enzymatic Degradation of Peptide Drugs by Intestinal Brush Border Membrane Vesicles,”International Journal of Pharmaceutics, 1996, pp. 39-52, vol. 141.
Schilling et al., “Intestinal Mucosal Transport and Metabolism of Insulin,”Department of Industrial and Physical Pharmacy, Purdue University, W. Lafayette, IN 47907, p. S-157, PDD 7184.
Schipper et al., “Chitosans as Absorption Enhancers of Poorly Absorbable Drugs; 3: Influence of Mucus on Absorption Enhancement,”European Journal of Pharmaceutical Sciences, 1999, pp. 335-343, vol. 8.
Thanou et al., “Effects ofN-Trimethyl Chitosan Chloride, a Novel Absorption Enhancer, on Caco-2 Intestinal Epithelia and the Ciliary Beat Frequency of Chicken Embryo Trachea,”International Journal of Pharmaceutics, 1999, pp. 73-82, vol. 185.
Tozaki et al., “Use of Protease Inhibitors to Improve Calcitonin Absorption from the Small and Large Intestine in Rats,”J. Pharm. Pharmacol., 1998, pp. 913-920, vol. 50.
Uchiyama et al., “Enhanced Permeability of Insulin Across the Rat Intestinal Membrane by Various Absorption Enhancers: Their Intestinal Mucosal Toxicity and Absorption-Enhancing Mechanism of n-Lauryl-β-D-Maltopyranoside,”J. Pharm. Pharmacol., 1999, pp. 1241-1250, vol. 51.
Wade et al., eds., “Polymethacrylates,”Handbook of Pharmaceutical Excipients, Second Edition, 1994, pp. 362-366, American Pharmaceutical Association, Washington, D.C.
“Aminoalkyl Methacrylate Copolymer E,” 1998, pp. 76-77.
Nakanishi Kiyo
Takemura Shigeo
Tsutsui Yuuki
Watanabe Shunsuke
Astellas Pharma Inc.
Azpuru Carlos A
Kilpatrick Townsend & Stockton LLP
LandOfFree
Pharmaceutical composition for oral use with improved... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical composition for oral use with improved..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical composition for oral use with improved... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2628898